GTC presented abstracts at AACR 2023
GTC’s posters from 2023 Convention of American Association for Cancer Research are now available to be downloaded. Please reach out with any questions.
Predicting PD-L1 Status in Solid Tumors Using Transcriptomic Data and Artificial Intelligence Algorithms
The Molecular Landscape of Premenopausal Versus Postmenopausal Breast Cancer in Patients Without Inherited Predisposition Mutations
Real-world transcriptomic biomarkers as replacement for immunohistochemistry and FISH studies in breast cancer
Read more Articles and News from GTC
BioAI and Genomic Testing Cooperative Announce Strategic Collaboration to Provide AI-Powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications
Manchester, NH – June 25, 2024 – BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology. GTC will become an early technology access member of BioAI’s global ecosystem of clinical laboratories.
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy
New publication in New England Journal of Medicine for Genomic Testing Cooperative (GTC). GTC work was in collaboration with Dana-Faber cancer Institute/Harvard Medical School, Georgetown